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Summary
Diaphyseal medullary stenosis with malignant fibrous
histiocytoma (DMS-MFH) is an autosomal dominant
bone dysplasia/cancer syndrome of unknown etiology.
This rare hereditary cancer syndrome is characterized
by bone infarctions, cortical growth abnormalities, path-
ological fractures, and eventual painful debilitation. No-
tably, 35% of individuals with DMS develop MFH, a
highly malignant bone sarcoma. A genome scan for the
DMS-MFH gene locus in three unrelated families with
DMS-MFH linked the syndrome to a region of ∼3 cM
on chromosome 9p21-22, with a maximal two-point
LOD score of 5.49 (marker D9S171 at recombination
fraction [v] .05). Interestingly, this region had previously
been shown to be the site of chromosomal abnormalities
in several other malignancies and contains a number of
genes whose protein products are involved in growth
regulation. Identification of this rare familial sarcoma-
causing gene would be expected to simultaneously define
the cause of the more common nonfamilial, or sporadic,
form ofMFH—a tumor that constitutes ∼6% of all bone
cancers and is the most frequently occurring adult soft-
tissue sarcoma.
Introduction
Diaphyseal medullary stenosis with malignant fibrous
histiocytoma (DMS-MFH) is a rare, autosomal domi-
nant bone dysplasia/cancer syndrome (MIM 112250) of
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unknown etiology (Arnold 1973; Hardcastle et al.
1986). The bone dysplasia is uniquely characterized by
cortical growth abnormalities, including diffuse DMS
with overlying endosteal cortical thickening and scal-
loping, metaphyseal striations, infarctions, and scattered
sclerotic areas of the long bones. Clinical features include
pathological fractures with subsequent poor healing or
nonunion, progressive wasting and bowing of the legs,
and painful debilitation. The development of presenile
cataracts has also been noted (Arnold 1973; Hardcastle
et al. 1986). Most notably, between the second and fifth
decades of life, 35% of DMS-MFH gene carriers develop
the bone sarcoma, MFH (Arnold 1973; Hardcastle et
al. 1986; Norton et al. 1996).
DMS-MFH is the only known familial form of MFH.
In its sporadic form, MFH accounts for ∼6% of all bone
tumors and is the most common adult soft-tissue sar-
coma (Mankin et al. 1991; Posner and Brennan 1991).
The tumor is believed to be of primitive mesenchymal
origin, representing a neoplasm arising from a histiocytic
cell or a “facultative fibroblast” (see Unni 1996). Al-
though molecular analyses of these tumors have begun
to reveal a number of prognostic markers (Brinck et al.
1995; Reid et al. 1996; Larramendy et al. 1997), no
consistent diagnostic molecular markers have been de-
fined (Szymanska et al. 1995; Larramendy et al. 1997;
Walter et al. 1997). Because sporadic and inherited can-
cer forms are often genetically equivalent (see Fearon
1997), identification of the DMS-MFH gene would elu-
cidate the molecular origins of a highly malignant
sarcoma.
Since the cause of DMS-MFH is unknown, our studies
have focused on identification of the DMS-MFH gene
by a positional cloning strategy. Three families with
DMS-MFH were recruited, and after a genomewide
search, linkage to chromosome region 9p21-22 was es-
tablished for the syndrome. Localization and character-
ization of the DMS-MFH gene will permit improved and
earlier diagnosis of at-risk patients, will further under-
standing of normal bone development and metabolism,
and will identify a novel tumor-suppressor gene.
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Patients and Methods
Sample Collection
After the subjects gave informed consent, blood sam-
ples were obtained from a total of 42 family members
and appropriate spouses from the three families with
DMS-MFH (Arnold 1973; Hardcastle et al. 1986; Nor-
ton et al. 1996). Immortalized lymphoblastoid cell lines
were established (Anderson and Gusella 1984), and
high-resolution cytogenetic analysis was performed
(Verma and Babu 1995) on an index patient from each
family. The disease status of each family member in-
cluded in this study was diagnosed by plain-film x-ray;
the findings are shown in figure 1.
Linkage Analysis
Microsatellite markers from the Human Screening
Panel, version 4.0 (Research Genetics), were used for the
genome scan. Additional markers to further define the
critical region were obtained (Research Genetics). PCR
amplifications were performed with a radioactively end-
labeled primer, as described elsewhere (Gelb et al. 1995).
Genotype data were entered into the LABMAN (Adams
1994) custom data management system, which gener-
ated the input files for linkage analysis. Two-point link-
age analysis was performed with the computer program
LINKAGE (version 5.1) and its associated subprograms
(Ott and Terwilliger 1994). DMS-MFH was assumed to
be a completely penetrant, genetically homogeneous, au-
tosomal dominant disease with an allele prevalence of
0.00001. Sex-averaged genetic recombination maps
were used to derive the intermarker distances.
Results
Linkage Analysis
The pedigrees of the three DMS-MFH families re-
cruited for our study were defined (fig. 1). Blood samples
were obtained with informed consent from 19, 3, and
20 informative family members (and from relevant
spouses) of families 1, 2, and 3, respectively. High-res-
olution cytogenetic analysis (1550 bands) performed on
peripheral leukocytes from an affected member of each
family revealed no abnormalities. A genomewide search
using PCR-based microsatellite screening markers at a
density of 10 cM was performed. Initial linkage to chro-
mosome region 9p21-22 was obtained with marker
D9S741, which gave a LOD score of Z  2.42 at re-
combination fraction (v)  .10. As shown in table 1,
subsequent analysis with 11 additional markers from the
region resulted in a maximal LOD score (Zmax) for
marker D9S171 of 5.49 at v  .05, exceeding the min-
imal threshold for linkage of 3.3 (Lander and Kruglyak
1995). Markers D9S1814, IFNA, D9S1846, and
D9S1870 had maximal positive LOD scores at v  .00.
The clinical and radiological findings in the three families
with DMS-MFH were identical, and positive LOD
scores consistent with the hypothesis that DMS-MFH is
genetically homogeneous were generated from all three
families.
Haplotype Analysis
Haplotype analysis was performed to define the
boundaries of the DMS-MFH locus. As shown in figure
2, a common DMS-MFH haplotype was present in four
of the affected members of family 1 (V-5, V-7, V-8, and
VI-7). The telomeric boundary of the region was defined
by a recombinant event between markers D9S1778 and
D9S1814 that was observed in affected individual VI-6.
Further support for the telomeric border was provided
by analysis of unaffected individual IV-6 in family 3,
who inherited her familial DMS-MFH haplotype begin-
ning at marker D9S1778 and extending telomeric to it.
Accordingly, the DMS-MFH locus was confined to the
region centromeric to D9S1778.
Haplotype analysis of affected individuals from family
3 defined the centromeric boundary of the locus. Af-
fected individual III-3 and her two affected descendants,
IV-9 and V-19, shared a DMS-MFH haplotype that dif-
fered from that of III-1 and her affected children, IV-2
and IV-5, by markers centromeric to D9S171. This in-
dicated an ancestral recombinant event betweenmarkers
D9S171 and D9S1679/D9S265. The DMS-MFH critical
region was further defined as telomeric to D9S171 by a
recombinant event between D9S1846/D9S1870 and
D9S171 in affected individual IV-7. The two affected
individuals in family 2, who shared identical haplotypes,
provided no additional information.
Discussion
As part of our overall approach to identify the genetic
defect underlying the hereditary skeletal dysplasia/bone
cancer syndrome DMS-MFH, a positional cloning strat-
egy was undertaken. A genomewide search of three mul-
tigenerational families with DMS-MFH, performed by
use of microsatellite markers, localized the DMS-MFH
gene to a region of ∼3 cM between markers D9S1778
and D9S171 on chromosome region 9p21-22.
The DMS-MFH locus was placed on the chromosome
9 cytogenetic map by reference to the previously posi-
tioned interferon gene (IFNA). IFNA, mapping near the
telomeric boundary of the DMS-MFH locus and pro-
ducing a maximal LOD score of 3.69 at v  .00 (table
1), had previously been assigned to 9p22 by in situ hy-
bridization (Trent et al. 1982). Molecular studies, per-
formed by means of loss of heterozygosity (LOH) map-
Figure 1 Pedigrees of the three DMS-MFH kindreds. Families 1 and 2 have been described elsewhere as the “American” and “Australian” families, respectively (Arnold 1973; Hardcastle et
al. 1986), and findings on their disease status are here updated. Family 3 is the recently described “New York” family (Norton et al. 1996). Family members classified as “suspected by history” were
unavailable for radiological diagnosis but had multiple (12) pathological fractures and/or had children radiologically diagnosed with DMS-MFH. Dysplasia was diagnosed by plain-film x-ray. The
identification numbers of individuals from whom blood samples were obtained are underlined.
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Table 1
Two-Point Linkage Data between the DMS-MFH
Locus and Chromosome 9 Polymorphic Markers
LOD SCORE AT v 
LOCUS .00 .01 .05 .10 .20
D9S156  1.62 .34 .09 .31
 1.46 .78 .52 .28
 .26 .29 .42 .36
 3.34 .83 .01 .39
D9S157  .94 1.38 1.35 .95
.26 .26 .22 .18 .11
 .02 .57 .67 .57
 1.22 2.17 2.20 1.63
D9S162 .56 .53 .43 .34 .20
.26 .26 .22 .18 .11
 .32 .87 .97 .84
 .05 .66 .81 .75
D9S1778  .53 .99 .99 .67
.26 .26 .23 .18 .11
.62 .73 .92 .95 .79
 1.52 2.14 2.12 1.57
IFNA 1.07 1.08 1.07 .99 .72
.26 .25 .22 .19 .11
2.36 2.32 2.15 1.92 1.44
3.69 3.65 3.44 3.10 2.27
D9S1814 .48 .46 .39 .30 .13
.22 .21 .18 .15 .09
2.60 2.55 2.36 2.11 1.58
3.30 3.22 2.93 2.56 1.80
D9S1846 .28 .26 .18 .11 .04
.26 .25 .23 .18 .11
.56 .55 .50 .44 .32
.54 .54 .55 .51 .39
D9S1870 2.22 2.20 2.10 1.91 1.42
.26 .25 .21 .18 .11
2.36 2.32 2.15 1.92 1.44
4.84 4.77 4.46 4.01 2.97
D9S171 4.82 4.73 4.40 3.96 3.01
.26 .26 .22 .18 .12
 .32 .87 .97 .84
 5.31 5.49 5.11 3.97
D9S1679 2.59 2.52 2.24 1.89 1.14
.26 .25 .22 .18 .12
 1.37 .12 .27 .44
 1.40 2.34 2.34 1.70
D9S265  .88 .27 .06 .05
.26 .25 .22 .18 .11
4.70 1.13 .48 .24 .07
 1.76 .53 .12 .09
NOTE.—Values given are pairwise cumulative LOD
scores (Z) between the DMS-MFH gene and nine
marker loci at different v values for the three families
with DMS-MFH, and their cumulative sums (i.e., in
descending order, families 1, 2, 3, and the cumulative
sum).
ping of bladder cancers, showed that the locus of the
commonly deleted region at chromosomal bands 9p21-
22 was between the interferon cluster andD9S171 (Stad-
ler et al. 1994). Therefore, the DMS-MFH locus was
assigned to the chromosomal region 9p21-22.
Comparison of the affected haplotypes revealed that
the two American kindreds, families 1 and 3, shared an
identical haplotype extending through the entire
D9S1778-D9S171 region. This finding most likely re-
flects a shared ancestor, because this haplotype is ap-
parently rare among whites, since it was not observed
among 64 unrelated chromosomes in the CEPH data-
base (Murray et al. 1994). The less likely possibility of
independent mutations on a common haplotype could
not be formally excluded. A detailed historical survey
of these two kindreds revealed no known common an-
cestral surnames; however, the three families shared an
English origin. Therefore, although we cannot defini-
tively discriminate between the genetic origins of families
1 and 2, the independent genotype of family 3 and the
positive LOD scores generated by this family remain
consistent with genetic homogeneity for DMS-MFH.
Haplotype analyses of the members of the families
with DMS-MFH had the additional benefit of ordering
several polymorphic markers that previously colocalized
on the Ge´ne´thon map. The independent recombinant
events between D9S1778 and D9S1814 observed in in-
dividuals VI-6 in family 1 and IV-6 in family 3 indicated
that D9S1778 was telomeric to D9S1814. Similarly, the
ancestral recombination observed in family 1 showed
that D9S171 was telomeric to D9S265 and D9S1679,
as shown in figure 2. Hence, the order “centromere-
[D9S265/D9S1679]-D9S171-D9S1814-D9S1778-telo-
mere” was established for these markers.
On the basis of the Ge´ne´thon 1996 human genetic
map (Dib et al. 1996), the genetic distance between
markers D9S1778 and D9S171 is ∼7 cM. However,
more-precise estimates indicate that the critical region is
∼3 cM. Cannon-Albright et al. (1994) estimated the ge-
netic distance between IFNA (which colocalized with
D9S1778 on the 1996 Ge´ne´thon human genetic map)
and D9S171 to be ∼2 cM. Fountain et al. (1992) esti-
mated the distance between IFNB, the most telomeric
member of the interferon superfamily gene cluster con-
taining IFNA, and D9S126, a marker that lies centrom-
eric to D9S171, to be ∼4.4 cM. Since D9S126 is 2 cM
centromeric to D9S171, the genetic distance between
IFNB and D9S171 on that map would be ∼2.4 cM. Since
markers D9S1778 and IFNB colocalize on the 1,140-
kb CEPH mega-YAC 763h4 (data not shown), the crit-
ical region is, at most, 3.5 cM.
The protein products of hereditary cancer genes have
been shown to be involved in a number of key aspects
of cellular growth and regulation, and, interestingly,
chromosome region 9p21-22 contains the tumor-sup-
pressor genes responsible for familial melanoma (Can-
non-Albright et al. 1994) and multiple familial tricho-
epithelioma (Harada et al. 1996). The region itself is one
of the most frequently deleted and/or translocated chro-
mosomal regions in human cancer (Mitelman 1994).
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Figure 2 DMS-MFH kindred haplotypes analyzed by nine informative markers (D9S157, D9S162, D9S1778, D9S1814, D9S1846,
D9S1870, D9S171, D9S1679, and D9S265) from the linkage region. Family and individual numberings are the same as in figure 1. Affecteds
are identified by an asterisk (*). Individual IV-8S in family 2 is the spouse of a deceased affected (IV-8), and her genotypic data were used to
determine chromosome origin.
Growth-regulating genes are plausible disease gene can-
didates for DMS-MFH, whose phenotype includes ex-
cessive endosteal bone formation and a predilection for
sarcomatous change. Among them, the best-character-
ized genes are CDKN2A and CDKN2B, which are cy-
clin-dependent kinase inhibitors, important negative reg-
ulators of cell division. In addition to being deleted on
both chromosomes in cell lines derived from lung, breast,
brain, bone, skin, bladder, kidney, ovary, and lympho-
cyte tumors, mutations in CDKN2A result in a form of
familial melanoma (Gruis et al. 1995). Sequence analysis
of the CDKN2A and CDKN2B genes (as well as their
splice variants) from individuals with DMS-MFH failed
to reveal any mutations. Similarly, other 9p21-22 can-
didate genes have been excluded, including RagA, a ras-
related GTP-binding protein (Bun-ya et al. 1992; Schur-
mann et al. 1995); AF-9, a putative transcription factor
in acute leukemia, cloned from a translocated region
involving chromosomes 9p22 and 11q23 (Nakamura et
al. 1993); and AK3, a nucleoside triphosphate-kinase
that regulates adenine and guanine nucleotide pools (Xu
et al. 1992).
Currently, cloning and analysis of several additional
genes in this region, defined by expressed sequence tags,
are under way and may facilitate the identification of
the DMS-MFH gene. Initial LOH studies on a number
of hereditary and sporadic forms of MFH have shown
the majority of tumor samples to have deletions within
the DMS-MFH locus (J. A. Martignetti, B. D. Gelb, H.
Pierce, and R. J. Desnick, unpublished data). These pre-
liminary results not only support a shared genetic eti-
ology between hereditary and sporadic forms of MFH,
but also are in accord with the DMS-MFH gene’s being
a tumor-suppressor gene. Identification of the DMS-
MFH gene will therefore allow presymptomatic diag-
nosis of DMS-MFH in patients and may provide insights
into the control of bone growth and the development of
bone tumors.
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